Background The programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1)
axis plays a central role in suppressing antitumor immunity; axis dysregulation can be used …

Aims Paclitaxel is a widely used anti‐neoplastic agent but has low oral bioavailability due to
gut extrusion by P‐glycoprotein (P‐gp). Oral paclitaxel could be more convenient, less …

Background: Tislelizumab, a humanized IgG4 mAb with high affinity and specificity for PD-1,
was engineered to minimize binding to FcɤR on macrophages, thus abrogating antibody …

Aims A previous study suggested that a thymine (THY) challenge dose could detect aberrant
pharmacokinetics in known cases of fluoropyrimidine toxicity compared with healthy …

Background Tislelizumab is an investigational monoclonal antibody with high affinity and
specificity for PD-1. Tislelizumab was engineered to minimize binding to FcγR on …

445 Background: Monoclonal antibodies (mAb) against programmed cell death-1 (PD-1)
have demonstrated antitumor activity across multiple malignancies. BGB-A317 is a …

BACKGROUND Lung cancer remains a major worldwide health problem, with an estimated
2.1 million new lung cancer cases and 1.8 million deaths predicted in 2018, representing …

313 Background: Docetaxel (D) chemotherapy is a standard of care in men with advanced
prostate cancer (APC), both metastatic castration sensitive (CS) and castration resistant …

2569 Background: Paclitaxel has poor oral bioavailability due to active excretion by p-
glycoprotein (Pgp) on intestinal epithelial cells. An oral formulation would reduce IV access …

Advances in treatment of metastatic urothelial carcinoma (UC) have stagnated over the past
3 decades; however, the monoclonal antibodies (mAbs) against immune checkpoint …